A Modified Intravitreal Methotrexate Protocol for the Prevention of Proliferative Vitreoretinopathy after Silicone Oil Removal

被引:0
作者
Liu, Tianyu [1 ,4 ]
Runner, Margaret [1 ,2 ]
Mahmoud, Tamer H. [1 ,3 ]
Capone, Antonio [1 ,3 ]
Drenser, Kimberly A. [1 ,3 ]
Randhawa, Sandeep [1 ,3 ]
Williams, George A. [1 ,3 ]
Faia, Lisa J. [1 ,3 ]
机构
[1] Associated Retinal Consultants, 3555 W 13 Mile Rd Ste LL-20, Royal Oak, MI 48073 USA
[2] Retina Ctr Texas, Dallas, TX USA
[3] Oakland Univ William Beaumont Sch Med, Dept Ophthalmol, Rochester, MI USA
[4] Associated Retinal Consultants, 3555 W 13 Mile Rd, Royal Oak, MI 48073 USA
来源
OPHTHALMOLOGY RETINA | 2025年 / 9卷 / 04期
关键词
RETINAL REDETACHMENT; EPIRETINAL MEMBRANE; DETACHMENT; VITRECTOMY; MANAGEMENT; OUTCOMES; SURGERY;
D O I
10.1016/j.oret.2024.10.006
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To utilize a modified intravitreal (IVT) methotrexate (MTX) protocol for the prevention of proliferative vitreoretinopathy (PVR) after silicone oil (SO) removal (SOR). Design: Single-center nonrandomized retrospective comparative case series. Subjects: Eyes with grade C PVR who underwent retinal detachment (RD) repair and SO placement between 2019 and 2022 with >6 months of follow-up after SOR. A control group of age-and sex-matched eyes was included. Methods: Eyes were treated with 1 of 2 MTX protocols. Eyes in Group 1 received 6 IVT MTX injections after SO placement and another 6 IVT MTX injections after SOR. Eyes in Group 2 received 6 IVT MTX after SO placement only. Each series of 6 IVT MTX injections (400 mg/0.1 mL) consisted of 3 injections every 2 weeks followed by 3 injections every 4 weeks. Main Outcome Measures: The primary outcome was the retinal attachment rate at 6 months post-SOR without redetachment or reoperation. Secondary outcomes included change in visual acuity and rates of complications after SOR. Results: Fifty-two eyes of 52 patients (13 Group 1, 13 Group 2, 26 control) (mean age 59.8 years, 80.8% male) were included with a mean follow-up of 31.0 months. In aggregate, Group 1 and Group 2 eyes received a median (interquartile range [IQR]) of 6 (5.25, 7) IVT MTX injections pre-SOR; eyes in Group 1 received a median (IQR) of 5 (3, 6) IVT MTX injections post-SOR. Twelve (92.3%) Group 1 eyes, 11(84.6%) Group 2 eyes, and 21 (80.8%) control eyes had primary retinal attachment at 6 months post-SOR (P > 0.05). Visual acuity outcomes did not significantly differ between groups (P > 0.05). Rates of epiretinal membrane (ERM) and cystoid macular edema (CME) were significantly lower in Group 1 eyes (7.7% and 15.4%) compared with Group 2 (53.8% and 92.3%) and control (44.3% and 65.4%) eyes, respectively (P < 0.05). Conclusions: The use of IVT MTX injections in eyes with PVR undergoing RD repair was associated with a high rate of primary retinal attachment after SOR. Eyes that received IVT MTX injections after SOR had significantly lower rates of ERM and CME than eyes that did not. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. (c) 2024 by the American Academy of Ophthalmology
引用
收藏
页码:314 / 321
页数:8
相关论文
共 42 条
[1]   Intravitreal Methotrexate [J].
Abdi, Fatemeh ;
Mohammadi, S. Saeed ;
Falavarjani, Khalil Ghasemi .
JOURNAL OF OPHTHALMIC & VISION RESEARCH, 2021, 16 (04) :657-669
[2]   Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant [J].
Acharya, Nisha R. ;
Vitale, Albert T. ;
Sugar, Elizabeth A. ;
Holbrook, Janet T. ;
Burke, Alyce E. ;
Thorne, Jennifer E. ;
Altaweel, Michael M. ;
Kempen, John H. ;
Jabs, Douglas A. .
OPHTHALMOLOGY, 2023, 130 (09) :914-923
[3]  
Aldeyra Therapeutics Inc, The GUARD Trial-Part 1: A phase 3 clinical trial of repeated intravitreal injections of ADX- 2191 versus standard-of-care for prevention of proliferative vitreoretinopathy
[4]   Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid [J].
Asaria, RHY ;
Kon, CH ;
Bunce, C ;
Sethi, CS ;
Limb, GA ;
Khaw, PT ;
Aylward, GW ;
Charteris, DG .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (11) :1439-1442
[5]  
Bach M, 2007, Invest Ophthalmol Vis Sci
[6]   Intravitreal Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment: A Systematic Review [J].
Balas, Michael ;
Abdelaal, Ahmed ;
Popovic, Marko M. ;
Kertes, Peter J. ;
Muni, Rajeev H. .
OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2022, 53 (10) :561-+
[7]   Slow-Release Dexamethasone in Proliferative Vitreoretinopathy [J].
Banerjee, Philip J. ;
Quartilho, Ana ;
Bunce, Catey ;
Xing, Wen ;
Zvobgo, Tapiwa M. ;
Harris, Nicola ;
Charteris, David G. .
OPHTHALMOLOGY, 2017, 124 (06) :757-767
[8]   SILICONE OIL REMOVAL .2. OPERATIVE AND POSTOPERATIVE COMPLICATIONS [J].
CASSWELL, AG ;
GREGOR, ZJ .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1987, 71 (12) :898-902
[9]   A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy [J].
Charteris, DG ;
Aylward, GW ;
Wong, D ;
Groenewald, C ;
Asaria, RHY ;
Bunce, C .
OPHTHALMOLOGY, 2004, 111 (12) :2240-2245
[10]   Proliferative vitreoretinopathy - developments in adjunctive treatment and retinal pathology [J].
Charteris, DG ;
Sethi, CS ;
Lewis, GP ;
Fisher, SK .
EYE, 2002, 16 (04) :369-374